|
|
|
|
LEADER |
00000cam a2200000Mu 4500 |
001 |
EBOOKCENTRAL_ocn437175624 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr mn|---||||| |
008 |
090817s2006 vtu ob 001 0 eng d |
040 |
|
|
|a MERUC
|b eng
|e pn
|c MERUC
|d YDXCP
|d IDEBK
|d OCLCQ
|d UKDOC
|d OCLCQ
|d STF
|d OCLCO
|d OCLCF
|d ZCU
|d OCLCQ
|d MERUC
|d OCLCQ
|d OCLCO
|d U3W
|d ICG
|d OCLCQ
|d TKN
|d DKC
|d AU@
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 171113825
|a 742300089
|a 814470596
|a 823137324
|
020 |
|
|
|a 9780080465975
|q (electronic bk.)
|
020 |
|
|
|a 0080465978
|q (electronic bk.)
|
020 |
|
|
|a 1280707607
|
020 |
|
|
|a 9781280707605
|
020 |
|
|
|z 0123693934
|q (alk. paper)
|
029 |
1 |
|
|a DEBBG
|b BV044122343
|
035 |
|
|
|a (OCoLC)437175624
|z (OCoLC)171113825
|z (OCoLC)742300089
|z (OCoLC)814470596
|z (OCoLC)823137324
|
050 |
|
4 |
|a RM301.63
|a RM301.63 .T36 2006eb
|
072 |
|
7 |
|a TDCW
|2 bicssc
|
082 |
0 |
4 |
|a 615.19
|a 615/.19 22
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Metcalf, Brian W.
|
245 |
1 |
0 |
|a Target Validation in Drug Discovery.
|
260 |
|
|
|a Burlington :
|b Elsevier,
|c 2006.
|
300 |
|
|
|a 1 online resource (293 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
505 |
0 |
|
|a Front Cover; Title Page; Copyright Page; Table of Contents; Preface; Contributors; Chapter 1 Generation of Transgenic Animals; Chapter 2 Target Validation in Chemogenomics; Chapter 3 Cetuximab (Erbitux®), An Anti-Epidermal Growth Factor Receptor Antibody for the Treatment of Metastatic Colorectal Cancer; Chapter 4 Monoclonal Antibody to HER-2 in Breast Cancer; Chapter 5 Validation of TNF as a Drug Target in Inflammatory Bowel Disease; Chapter 6 Anti-CCL-2/MCP-1: Directed Biologicals for Inflammatory and Malignant Diseases; Chapter 7 Targeting IL-12p40 for Immune-Mediated Disease.
|
505 |
8 |
|
|a Chapter 8 The GPIIb/IIIa Antagonist Abciximab for Acute Percutaneous Coronary InterventionChapter 9 Epidermal Growth Factor Receptor (EGFR) Inhibitor for Oncology: Discovery and Development of Erlotinib; Chapter 10 Progress in Achieving Proof of Concept for p38 Kinase Inhibitors; Chapter 11 IKK-2/NF-kappa B-Dependent Transcription; Chapter 12 TNF Signaling Pathway Inhibitors for Inflammation-CCR2 Antagonists; Cha.
|
520 |
|
|
|a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics.
|
588 |
0 |
|
|a Print version record.
|
504 |
|
|
|a Includes bibliographical references and index.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Drug development.
|
650 |
|
0 |
|a Drugs
|x Testing.
|
650 |
|
0 |
|a High throughput screening (Drug development)
|
650 |
|
6 |
|a Médicaments
|x Développement.
|
650 |
|
6 |
|a Médicaments
|x Essais cliniques.
|
650 |
|
6 |
|a Criblage à haut débit (Développement des médicaments)
|
650 |
|
7 |
|a Drug development
|2 fast
|
650 |
|
7 |
|a Drugs
|x Testing
|2 fast
|
650 |
|
7 |
|a High throughput screening (Drug development)
|2 fast
|
700 |
1 |
|
|a Dillon, Susan.
|
776 |
1 |
|
|z 9780123693938
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=282102
|z Texto completo
|
938 |
|
|
|a 123Library
|b 123L
|n 44592
|
938 |
|
|
|a ProQuest MyiLibrary Digital eBook Collection
|b IDEB
|n 70760
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 2585775
|
994 |
|
|
|a 92
|b IZTAP
|